丙酸氟替卡松联合孟鲁司特在儿童支气管哮喘合并变应性鼻炎治疗中的价值研究  

Study on value of fluticasone propionate combined with montelukast in the treatment of children with bronchial asthma and allergic rhinitis

作　　者：田巧焕 魏浩兰[2] TIAN Qiao-huan;WEI Hao-lan(Department of Pediatrics,Liaocheng Third People's Hospital,Liaocheng 252000,China)

机构地区：[1]聊城市第三人民医院儿科,252000 [2]聊城市人民医院儿科,252000

出　　处：《中国实用医药》2024年第3期15-18,共4页China Practical Medicine

摘　　要：目的探讨于儿童支气管哮喘合并变应性鼻炎患儿中应用丙酸氟替卡松联合孟鲁司特治疗的临床效果。方法选取支气管哮喘合并变应性鼻炎患儿60例,选择随机数字表法分为对照组和观察组,各30例。对照组实施丙酸氟替卡松治疗,观察组应用丙酸氟替卡松联合孟鲁司特治疗。比较两组临床治疗效果,肺功能指标(用力肺活量、呼气峰值流速、第1秒用力呼气容积),哮喘症状和鼻炎症状评分,炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平,不良反应发生情况。结果①观察组治疗总有效率为96.67%,高于对照组的73.33%(P<0.05)。②治疗后,两组用力肺活量、呼气峰值流速、第1秒用力呼气容积均升高,且观察组用力肺活量(3.99±1.03)L、呼气峰值流速(172.32±27.53)L/min、第1秒用力呼气容积(2.64±0.62)L高于对照组的(3.36±0.97)L、(154.37±27.42)L/min、(1.97±0.56)L,差异显著(P<0.05)。③治疗后,两组哮喘症状和鼻炎症状评分均降低,且观察组哮喘症状评分(4.93±1.96)分和鼻炎症状评分(3.52±1.27)分低于对照组的(6.60±2.22)、(4.21±1.38)分,差异显著(P<0.05)。④治疗后,两组IL-6和TNF-α水平均降低,且观察组IL-6(93.80±23.63)ng/L和TNF-α(313.51±37.16)ng/L低于对照组的(109.49±26.38)、(351.40±46.38)ng/L,差异显著(P<0.05)。⑤两组不良反应发生率比较,无显著差异(P>0.05)。结论支气管哮喘合并变应性鼻炎患儿应用丙酸氟替卡松联合孟鲁司特治疗的临床效果突出显著,不仅能够有效改善患儿的哮喘症状和鼻炎症状,同时可改善患儿肺功能和炎症因子水平,建议广泛应用于临床治疗中。Objective To explore the clinical effect of fluticasone propionate combined with montelukast in the treatment of children with bronchial asthma and allergic rhinitis.Methods A total of 60 children with bronchial asthma and allergic rhinitis were selected and divided into the control group and the observation group by random number table,each with 30 cases.The control group was treated with fluticasone propionate,and the observation group was treated with fluticasone propionate and montelukast.Both groups were compared in terms of clinical effect,lung function indicators(forced vital capacity,peak expiratory flow rate,forced expiratory volume in one second),scores of asthma symptoms and rhinitis symptoms,levels of inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],and occurrence of adverse reactions.Results(i)The total effective rate of the observation group was 96.67%,which was higher than 73.33%of the control group(P<0.05).(ii)After treatment,the forced vital capacity,peak expiratory flow rate and forced expiratory volume in one second were increased in both groups;the forced vital capacity in the observation group was(3.99±1.03)L,the peak expiratory flow rate was(172.32±27.53)L/min and the forced expiratory volume in one second was(2.64±0.62)L,which were higher than(3.36±0.97)L,(154.37±27.42)L/min and(1.97±0.56)L in the control group;the difference was significant(P<0.05).(iii)After treatment,the scores of asthma symptoms and rhinitis symptoms in both groups were decreased;and the scores of asthma symptoms and rhinitis symptoms in the observation group were(4.93±1.96)and(3.52±1.27)points,which were lower than(6.60±2.22)and(4.21±1.38)points in the control group;the difference was significant(P<0.05).(iv)After treatment,the levels of IL-6 and TNF-αwere decreased in both groups;and the observation group had IL-6 of(93.80±23.63)ng/L and TNF-αof(313.51±37.16)ng/L,which were lower than(109.49±26.38)and(351.40±46.38)ng/L in the control group;the difference was significant(P<0.05

关 键 词：丙酸氟替卡松 孟鲁司特 儿童支气管哮喘 变应性鼻炎 

分 类 号：R725.6[医药卫生—儿科] R765.21[医药卫生—临床医学]